From the rising impact of diseases such as depression and obesity to the rapid expansion of medical data, many of the challenges facing global health care systems represent new aspects of foundational issues. In this Bulletin, leaders of Analysis Group’s Health Care practice draw on their experience and research to offer insights to improve decision making and outcomes.
The economic ripples of major depressive disorder (MDD) are extensive and disproportionate to the amount spent on the disease itself.
The use of big data and related analytics is increasingly widespread in health care. In a recent conversation, Principal Howard Birnbaum met with Managing Principals Mei Sheng Duh and Eric Wu to discuss the future of medical big data research.
As the quantity of available data increases and traditional processing approaches become cumbersome and costly, Analysis Group teams have utilized a novel approach: leveraging the graphic processing unit (GPU) cores in graphics cards for parallel processing.
Rising obesity levels are now responsible for more than one-quarter of total health care expenditures in the United States and may become the single largest driver of mortality other than aging.
Zachary Dyckman, a health economist and Analysis Group affiliate, discusses trends and recent litigation related to provider balance billing – which occurs when out-of-network (OON) health care providers bill patients for the difference between a billed charge and a health plan’s allowed amount.
Despite a large and growing unmet need, anti-obesity drug product launches slowed in the 1990s and early 2000s following a series of withdrawals, failures, and significant litigation settlements.
Leaders of Analysis Group’s Health Care practice have been
consistently recognized as industry leaders at leading international
conferences and have also been involved in significant trends in health care
Researchers from Analysis Group's Health Care practice
presented one educational symposium and one workshop, and exhibited 24 posters,
at the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual
International Meeting. Three posters supported by Analysis Group
researchers received finalist
ribbons. The research, covering tuberous sclerosis complex, obesity, and
migraines, involved Managing Principals Mei Sheng Duh and Edward Tuttle,
Principal Howard Birnbaum, Vice Presidents Noam Kirson and Francis Vekeman, and
Managers Rajeev Ayyagari and Amie Shei.
In August 2015, a group of prominent economists that
included senior staff members Bruce Stangle, Paul Greenberg, Pierre Cremieux,
and George Kosicki, and academic economists James Hughes, Keith Hylton, Edward
Snyder, and Michael Wohlgenant filed
an amicus curiae brief regarding issues in the antitrust treatment of
pharmaceutical patent infringement settlements. In January 2015, senior
firm members Bruce Stangle and Paul Greenberg, and academic economists Henry
Grabowski, James Hughes, John Rizzo, Edward Snyder, and Michael Wohlgenant, filed
an amicus curiae brief regarding a pharmaceutical manufacturer’s freedom
to withdraw a branded product from the market prior to generic entry.
Health Care Bulletin: Fall 2015